phase readout
savePhase 3 primary completion: Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
February 25, 2040updated 21d ago
community read0 votes
Sponsor: Pfizer. Status: Recruiting. Conditions: Hemophilia A, Hemophilia B. NCT05568719.
view source ↗Data sources
last refreshed just now
Found something off?
comments(0)
5-min edit window · permanent after that